Please assess the completion status of the following clinical trial:

Trial Title: Evaluation of the Efficacy and Safety of Bempedoic Acid (ETC-1002) 180mg, Ezetimibe 10mg, and Atorvastatin 20 mg Triplet Therapy in Patients With Elevated LDL-C

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Fasting LDL-cholesterol between 130 - 189 mg/dL at screening following washout of all LDL-C-lowering drugs and nutritional supplements~* Men and nonpregnant, nonlactating women~* Sufficiently stable and suitable to undergo washout of all LDL-C-lowering drugs and nutritional supplements for 12 weeks~Exclusion Criteria:~* Fasting blood triglycerides greater than or equal to 400 mg/dL~* Body Mass Index (BMI) greater than 50 kg/m2~* History of clinically significant cardiovascular disease~* History of type 1 or type 2 diabetes

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Triplet Therapy (Type: EXPERIMENTAL): Bempedoic acid 180 mg, ezetimibe 10 mg, and atorvastatin 20 mg taken orally, daily.
- placebo (Type: PLACEBO_COMPARATOR): Matching placebos taken orally, daily.

Based on this trial design, predict the completion outcome and termination type (if applicable).